Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451488 · ClinicalTrials.gov registry record · Phase 4
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
A Phase 4 study of Melanoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02451488: Completed Phase 4 study of Melanoma, sponsored by Mayo Clinic.
NCT02451488 is a Phase 4 study of Melanoma that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02451488, a Phase 4 study of Melanoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
Primary Outcome
The Th1/Th2/Th3 Reverse transcription polymerase chain reaction (RT-qPCR) arrays will be used to quantify RNA expression of Th1 and Th2 messenger ribonucleic acids (mRNAs). Normalized gene expression was calculated from qRT-PCR results comparing GM-CSF and control subjects for both Th1-associated gene T-bet and Th2-associated gene GATA3 respectively. Fold change values are calculated by taking the normalized gene expression in GM-CSF treated group samples divided by the normalized gene expressio
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG GM-CSF
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 4 |
What the finished NCT02451488 record still lists
NCT02451488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT02451488 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02451488 about?
NCT02451488 is a clinical study titled "Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma". Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
What is the current status of trial NCT02451488?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2015-05. Estimated completion is 2016-11-04.
What conditions does trial NCT02451488 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT02451488?
The interventions under investigation include: Standard of Care (OTHER), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT02451488?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02451488 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02451488's enrollment target sits among peer trials
8 255th of 266 higher than 10 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Can We Miss Pigmented Lesions in Psoriasis Patients?
COMPLETED · Phase 4
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia